发明公开
EP3228315A1 PREVENTION OF ADVERSE EFFECTS CAUSED BY CD3 SPECIFIC BINDING DOMAINS
审中-公开
预防由CD3特异性结合域引起的不良影响
- 专利标题： PREVENTION OF ADVERSE EFFECTS CAUSED BY CD3 SPECIFIC BINDING DOMAINS
- 专利标题（中）： 预防由CD3特异性结合域引起的不良影响
-
申请号： EP17159560.6申请日： 2011-10-27
-
公开(公告)号： EP3228315A1公开(公告)日： 2017-10-11
- 发明人: ZUGMAIER, Gerhard , NAGORSEN, Dirk , SCHEELE, Juergen
- 申请人： Amgen Research (Munich) GmbH
- 申请人地址： Staffelseestrasse 2 81477 München DE
- 专利权人： Amgen Research (Munich) GmbH
- 当前专利权人： Amgen Research (Munich) GmbH
- 当前专利权人地址： Staffelseestrasse 2 81477 München DE
- 代理机构： Schiweck, Weinzierl & Koch Patentanwälte Partnerschaft mbB
- 优先权： US412229P 20101110
- 主分类号： A61K31/573
- IPC分类号： A61K31/573 ; A61K39/395 ; C07K16/28
摘要：
The present invention relates to a glucocorticoid (GC) for use in the amelioration, treatment or prophylaxis of neurological/psychiatric adverse events caused by a CD3 binding domain. Kits comprising a GC, a CD3 binding domain and instructions for use which indicate that the GC is to be employed for the treatment amelioration and/or prophylaxis of neurological adverse events caused by said CD3 binding domain, are also disclosed.
公开/授权文献
信息查询
